Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:LXRX
  • CUSIP: 52887210
  • Web: www.lexpharma.com
Capitalization:
  • Market Cap: $1.53 billion
  • Outstanding Shares: 105,235,000
Average Prices:
  • 50 Day Moving Avg: $15.12
  • 200 Day Moving Avg: $15.15
  • 52 Week Range: $12.94 - $19.62
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.13
  • P/E Growth: -0.18
Sales & Book Value:
  • Annual Revenue: $89.14 million
  • Price / Sales: 17.14
  • Book Value: $1.28 per share
  • Price / Book: 11.34
Profitability:
  • EBIDTA: ($143,170,000.00)
  • Net Margins: -11.87%
  • Return on Equity: -9.46%
  • Return on Assets: -3.80%
Debt:
  • Debt-to-Equity Ratio: 0.46%
  • Current Ratio: 2.34%
  • Quick Ratio: 2.34%
Misc:
  • Average Volume: 905,740 shs.
  • Beta: 0.6
  • Short Ratio: 12.34
 

Frequently Asked Questions for Lexicon Pharmaceuticals (NASDAQ:LXRX)

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Friday, March, 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.20. The business had revenue of $23 million for the quarter, compared to analyst estimates of $15.56 million. Lexicon Pharmaceuticals had a negative return on equity of 9.46% and a negative net margin of 11.87%. Lexicon Pharmaceuticals's revenue for the quarter was down 81.9% compared to the same quarter last year. During the same period last year, the company earned $0.76 EPS. View Lexicon Pharmaceuticals' Earnings History.

When will Lexicon Pharmaceuticals make its next earnings announcement?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Lexicon Pharmaceuticals.

Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?

6 brokers have issued 12-month target prices for Lexicon Pharmaceuticals' stock. Their forecasts range from $21.00 to $38.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $28.00 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.

What are analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

  • 1. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
  • 2. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)
  • 3. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (2/17/2017)

Who are some of Lexicon Pharmaceuticals' key competitors?

Who owns Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (4.00%), Eagle Asset Management Inc. (2.73%), NEA Management Company LLC (2.28%), Kingdon Capital Management L.L.C. (1.61%) and State Street Corp (1.56%). View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., TIAA CREF Investment Management LLC, Goldman Sachs Group Inc., Columbus Circle Investors, Moody Aldrich Partners LLC, Teachers Advisors LLC, SG Americas Securities LLC and KCG Holdings Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Highbridge Capital Management LLC, Point72 Asset Management L.P., Sector Gamma AS, Renaissance Technologies LLC, Kingdon Capital Management L.L.C., Bank of America Corp DE and Old Mutual Global Investors UK Ltd.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy Lexicon Pharmaceuticals stock?

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Lexicon Pharmaceuticals stock cost?

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $14.52.

Analyst Ratings

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $28.00 (92.84% upside)

Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017HC WainwrightSet Price TargetBuy$27.00HighView Rating Details
4/5/2017Needham & Company LLCReiterated RatingBuy$21.00MediumView Rating Details
3/7/2017Citigroup IncBoost Price TargetBuy$24.00 -> $28.00N/AView Rating Details
3/1/2017WedbushBoost Price TargetOutperform -> Outperform$33.00 -> $38.00N/AView Rating Details
12/23/2016Cowen and CompanyReiterated RatingMarket PerformN/AView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$25.00 -> $26.00N/AView Rating Details
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$16.00N/AView Rating Details
9/28/2015GabelliUpgradeSell -> Hold$13.50N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Earnings by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Earnings History by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
3/3/2017Q4 2016($0.51)($0.31)$15.56 million$23.00 millionViewN/AView Earnings Details
11/1/2016Q316($0.50)($0.35)$9.68 million$27.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.40)($0.37)$12.36 million$20.10 millionViewN/AView Earnings Details
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details
11/6/2015Q3($0.36)($0.34)$0.44 million$0.57 millionViewN/AView Earnings Details
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details
11/4/2014Q3($0.05)($0.05)$0.16 million$0.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
2017 EPS Consensus Estimate: ($1.70)
2018 EPS Consensus Estimate: ($1.11)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.47)($0.47)($0.47)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.46)($0.46)($0.46)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.39)($0.39)($0.39)
Q3 20181($0.32)($0.32)($0.32)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Ownership Percentage: 5.40%
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016James F TessmerVPSell1,500$15.00$22,500.00View SEC Filing  
5/23/2016James F TessmerVPSell6,000$13.00$78,000.00View SEC Filing  
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Source:
DateHeadline
seekingalpha.com logoLexicon Pharmaceuticals (LXRX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 24 at 10:56 AM
finance.yahoo.com logoETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 5:57 PM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : May 18, 2017
finance.yahoo.com - May 18 at 8:45 AM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $17.98 Million
www.americanbankingnews.com - May 12 at 1:52 PM
prnewswire.com logoLexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In ... - PR Newswire (press release)
www.prnewswire.com - May 11 at 6:53 PM
finance.yahoo.com logoLexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
finance.yahoo.com - May 11 at 6:53 PM
finance.yahoo.com logoETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 6:53 PM
americanbankingnews.com logoZacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (LXRX) to Post -$0.44 Earnings Per Share
www.americanbankingnews.com - May 10 at 4:26 PM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 11:55 AM
americanbankingnews.com logoGabelli Comments on Lexicon Pharmaceuticals, Inc.'s FY2017 Earnings (LXRX)
www.americanbankingnews.com - May 8 at 9:48 AM
americanbankingnews.com logoHC Wainwright Reiterates $27.00 Price Target for Lexicon Pharmaceuticals, Inc. (LXRX)
www.americanbankingnews.com - May 7 at 10:02 PM
americanbankingnews.com logoGabelli Comments on Lexicon Pharmaceuticals, Inc.'s FY2019 Earnings (LXRX)
www.americanbankingnews.com - May 5 at 7:58 PM
prnewswire.com logoLexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:48 AM
finance.yahoo.com logoLexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - May 4 at 6:29 PM
finance.yahoo.com logoEdited Transcript of LXRX earnings conference call or presentation 2-May-17 10:00pm GMT
finance.yahoo.com - May 4 at 11:48 AM
marketbeat.com logoLexicon reports 1Q loss
marketbeat.com - May 3 at 5:16 AM
finance.yahoo.com logoLexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update
finance.yahoo.com - May 2 at 7:42 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 1 at 12:28 PM
finance.yahoo.com logoLexicon Pharmaceuticals To Host First Quarter 2017 Financial ... - Yahoo Finance
finance.yahoo.com - April 29 at 12:20 AM
americanbankingnews.com logoLexicon Pharmaceuticals (LXRX) Receiving Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 8:20 PM
prnewswire.com logoLexicon Pharmaceuticals To Host First Quarter 2017 Financial ... - PR Newswire (press release)
www.prnewswire.com - April 28 at 7:19 PM
finance.yahoo.com logoLexicon Pharmaceuticals To Host First Quarter 2017 Financial Results Conference Call And Webcast On May 2, 2017
finance.yahoo.com - April 28 at 7:19 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $14.81 Million
www.americanbankingnews.com - April 27 at 1:14 AM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : April 26, 2017
finance.yahoo.com - April 26 at 6:54 PM
americanbankingnews.com logoLexicon Pharmaceuticals (LXRX) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 25 at 9:24 PM
finance.yahoo.com logoETFs with exposure to Lexicon Pharmaceuticals, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 5:47 PM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : April 25, 2017
finance.yahoo.com - April 25 at 10:27 AM
americanbankingnews.com logoLexicon Pharmaceuticals (LXRX) Receives Daily News Impact Score of 0.07
www.americanbankingnews.com - April 22 at 1:59 PM
seekingalpha.com logoLexicon Pharmaceuticals, Inc. (LXRX)
seekingalpha.com - April 21 at 6:15 PM
americanbankingnews.com logo-$0.44 EPS Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - April 19 at 6:18 PM
americanbankingnews.com logoLexicon Pharmaceuticals (LXRX) Getting Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 17 at 9:03 PM
finance.yahoo.com logoLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : April 14, 2017
finance.yahoo.com - April 14 at 8:54 AM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Receives Buy Rating from Needham & Company LLC
www.americanbankingnews.com - April 5 at 4:09 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 2:00 PM
us.rd.yahoo.com logoLexicon To Present At The 16th Annual Needham Healthcare Conference
us.rd.yahoo.com - April 4 at 9:05 AM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Short Interest Update
www.americanbankingnews.com - March 26 at 7:23 AM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Lexicon (LXRX)
finance.yahoo.com - March 15 at 6:38 PM
nasdaq.com logoLexicon Pharmaceuticals (LXRX) Shares Cross Below 200 DMA
www.nasdaq.com - March 13 at 6:09 PM
finance.yahoo.com logoLEXICON PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 9 at 6:13 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Lexicon Pharmaceuticals, Inc. Increased by Analyst (LXRX)
www.americanbankingnews.com - March 9 at 12:22 PM
finance.yahoo.com logoLexicon To Present At The Barclays Global Healthcare Conference
finance.yahoo.com - March 9 at 8:29 AM
seekingalpha.com logoLexicon Pharmaceuticals (LXRX) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 7:10 PM
americanbankingnews.com logoLexicon Pharmaceuticals, Inc. (LXRX) Price Target Raised to $28.00 at Citigroup Inc
www.americanbankingnews.com - March 7 at 9:09 PM
biz.yahoo.com logoLEXICON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 6 at 5:56 PM
finance.yahoo.com logo7:05 am Lexicon Pharma beats by $0.20, beats on revs
finance.yahoo.com - March 4 at 6:33 PM
finance.yahoo.com logoEdited Transcript of LXRX earnings conference call or presentation 3-Mar-17 3:00pm GMT
finance.yahoo.com - March 3 at 11:25 PM
us.rd.yahoo.com logoLexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
us.rd.yahoo.com - March 3 at 6:22 PM
sg.finance.yahoo.com logoLexicon reports 4Q loss
us.rd.yahoo.com - March 3 at 6:22 PM
biz.yahoo.com logoLEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
us.rd.yahoo.com - March 3 at 6:22 PM
finance.yahoo.com logoWedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential
finance.yahoo.com - March 3 at 6:22 PM

Social

Chart

Lexicon Pharmaceuticals (LXRX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff